Details for Patent: 8,361,972
✉ Email this page to a colleague
Which drugs does patent 8,361,972 protect, and when does it expire?
Patent 8,361,972 protects QTERN, BYDUREON, BYDUREON PEN, BYDUREON BCISE, and FARXIGA, and is included in four NDAs.
Protection for BYDUREON has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has sixty patent family members in twenty-seven countries.
Summary for Patent: 8,361,972
| Title: | Pharmaceutical formulations containing an SGLT2 inhibitor |
| Abstract: | Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate ##STR00001## and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release. |
| Inventor(s): | Bindra; Dilbir S. (New Brunswick, NJ), Dali; Mandar V. (New Brunswick, NJ), Parab; Prakash V. (New Brunswick, NJ), Patel; Jatin M. (New Brunswick, NJ), Tao; Li (New Brunswick, NJ), Tejwani; Ravindra W. (New Brunswick, NJ), Vatsaraj; Nipa (New Brunswick, NJ), Wu; Yongmei (New Brunswick, NJ) |
| Assignee: | Bristol Myers-Squibb Company (Princeton, NJ) |
| Application Number: | 13/529,463 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,361,972 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 8,361,972
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 209091-002 | May 2, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 209091-001 | Feb 27, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 209091-001 | Feb 27, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN | ⤷ Sign Up | ||||
| Astrazeneca Ab | QTERN | dapagliflozin; saxagliptin hydrochloride | TABLET;ORAL | 209091-001 | Feb 27, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF TYPE 2 DIABETES MELLITUS | ⤷ Sign Up | ||||
| Astrazeneca Ab | BYDUREON | exenatide synthetic | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 022200-001 | Jan 27, 2012 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,361,972
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2139494 | ⤷ Sign Up | PA2020522 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2139494 | ⤷ Sign Up | CA 2020 00035 | Denmark | ⤷ Sign Up |
| European Patent Office | 2139494 | ⤷ Sign Up | 301054 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2139494 | ⤷ Sign Up | 122020000043 | Germany | ⤷ Sign Up |
| European Patent Office | 2139494 | ⤷ Sign Up | LUC00176 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
